Sign In
Last checked at 
19 Mar 2015 13:45
ο»Ώ
Β
Hikma Pharmaceuticals PLC - Vesting of 2012 LTIP
Β
LONDON, 19 March 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 19 March 2015 under the 2005 Long Term Incentive Plan ("LTIP"). These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is Β£nil. The persons concerned have retained all the shares exercised.
Β
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.
Β
Bassam Kanaan Β | Vesting of LTIP 2012 | 46,300 (0.02% ISC) | 19 March 2015 | Β£22.26 | Nil | 500,390 (0.25% ISC) | |
Michael Raya Β | Vesting of LTIP 2012 | 43,800 (0.02% ISC) | 19 March 2015 | Β£22.26 | Nil | 119,960 (0.06% ISC) | |
Riad Mishlawi | Vesting of LTIP 2012 | 20,700 (0.01% ISC) Β | 19 March 2015 | Β£22.26 | Nil | 100,027 (0.05% ISC) | |
Khalid Nabilsi | Vesting of LTIP 2012 | 26,000 (0.01% ISC) Β | 19 March 2015 | Β£22.26 | Nil | 222,858 (0.11% ISC) | |
Β "ISC" = Issued Share Capital of Hikma which is 198,879,939 Ordinary Shares following the release of the LTIP 2012 | Β | ||||||
- ENDS -
Β
Enquiries
Peter Speirs +44 20 7399 2760
Company Secretary, Hikma Pharmaceuticals PLC
Β
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.
Β
Follow the stocks
